https://www.selleckchem.com/pr....oducts/z-vad(oh)-fmk
The fasting triglyceride and low-density lipoprotein cholesterol (LDL-C) levels decreased from baseline by an average of 43% and 60%, respectively. Hepatic steatosis decreased from baseline grade 3 to post-treatment grade 1. Hepatic fibrosis did not advance following 104 weeks of treatment with rhSA and regressed in one sibling. CONCLUSION Treatment with rhSA for 104 weeks in four siblings with LAL-D demonstrated improvement in their hepatic transaminase and serum lipid levels, accompanied by reduction of hepatic steatosis and no
Like
Comment
Share
